Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Rev. argent. endocrinol. metab ; 44(2): 67-77, abr.-jun. 2007. graf, tab
Article in Spanish | LILACS | ID: lil-641907

ABSTRACT

En el CDT es indispensable elevar los valores de TSH para efectuar Tg y barrido (RCT) con 131I, debiéndose suspender la opoterapia (HT) durante 4/5 sem. con el consecuente hipotiroidismo (H) y los trastornos que conlleva. Nuestro objetivo fue incrementar en forma rápida TSH-E acortando el tiempo de abstinencia. Se efectuaron 43 estudios en 37 pacientes con CDT (G-1); de entre 19 y 78 años, 34 con forma papilar y 3 folicular de CDT, 12 de sexo masculino y 25 femenino Se consideraron 2 subgrupos, G-1A, 7 p. para ablación (A); G-1B, 36 p. para seguimiento (S) y/o tratamiento (T) entre 6 meses y 5 años poscirugía; 6 p. efectuaron dos estudios, 4 para A y S y 2 para 2 veces S. Como comparación se revisaron 41 estudios en 35 p (G-2) que efectuaron suspensión de opoterapia por 4/5 semanas, entre 18 y 81 años; 28 de sexo femenino y 7 masculino; 32 papilares y 3 foliculares; 18 para A (G-2 A) y 21 para S, primer control (G-2B); 4 p. efectuaron 2 estudios, A y S. G-1A: entre 8/10 días poscirugía se les administra TRH 200 mcg i.v los días 1, 3, 5 y 6. A los 30 min de la 3ra aplicación, determinación de TSH y RCT con 370 MBq de 99mT; a igual lapso en la 4ta aplicación determinación de TSH, Tg y antiTg y 5,55 o 7,4 GBq de 131I, para A; a los 8 días RCT con 131I. G-1B: se suspende T4 y reemplaza por T3 por 3 semanas. Se suspende T3; a las 24 horas se inicia el esquema indicado para G-1A . A la 4ta aplicación de TRH, se administra el 131I, 14,8 MBq y RCT a las 48 horas en S o la actividad terapéutica indicada para T. En ambos grupos se indicó dieta hipoyódica. Resultados: En G-1, los valores de TSH ascendieron a 26-360 UI/L; promedio 83 UI/L ± 54; G-1A : 137 ±109; G-1B 7, 62 ± 52 . Los RCT no mostraron diferencias con ambos trazadores. En G-1A todos los p presentaron remanentes tiroideos y Tg positivas. En G-1B, 21 p. mostraron RCT y Tg negativas; 7 áreas activas y Tg positivas y 8 p RCT negativos con valores elevados de Tg . En G-2, TSH, 23-170 UI/L ( 63 ± 3 UI/L) ; G-2 A: 71 ± 41 ; G-2B, 63 ± 42. Conclusiones: Estos hallazgos indican que a) la metodología propuesta es adecuada para acortar sensible-mente el tiempo de abstinencia de opoterapia y reducir la sintomatología del H que pasa desapercibida en la mayoría de los casos; b) los valores de TSH-En obtenidos son similares y aun superiores a los alcanzados por suspensión de opoterapia por lapsos prolongados; c) el empleo del RCT con 99mTc como indicador de tejido captante disminuye el uso terapéutico a ciegas de 131I al señalar casos de ausencia de concentración y permite, cuando sea necesario, obtener anticipadamente 131I para su empleo terapéutico.


In the follow up (F) of p with DTC it is necessary to obtain high figures of serum TSH for determination of serum Tg and 131I scan (WBS). For this object, he method, for a long time, was to withdrawal thyroid hormone therapy (generally l-T4) that produce hypothyroidism with the inconvenient for the p, dramatics in certain cases. Our objective was to increase TSH by IS to shortening time of L-T4 withdrawal for F, ablation (A) or treatment (T) with 131I. In 37 p. with DTC (G-1), aged 19-78 y., 34 with pap. DTC and 3 with foll. form, 25 females, 12 males, 43 studies were carried out; 6 p carried 2 studies. The group was divided in 2 sub-groups: G-1A,7 p derived for A; G-1 B 36 p. for F or T with 131I. Six p carried out 2 studies; 4 of them for A and for F and 2 realizes 2 times F. All p treated with l-T4 replaced this hormone for T3 during 3 weeks ,that was withdrawal the day before IS. In G-1A, between 8/10 days after surgery they begin IS. IS: At days 1, 3, 5 and 6, the p were injected i.v. with 200 mcg of TRH; at 30 minutes of the 3rd injec. blood TSH determination ; immediately 370 MBq of 99mT was administered and at 30 minutes a WBS was carried out. At 30 minutes of the 4th injec. blood figures of TSH, Tg and Tg-ab were determined; immediately the activity of 131I indicated for each group was given to the p; in G-1A, at 8 days and in G1-B, at 48 hours WBS were carried out. As a control group (G-2) 41 studies in 35 DTC p. that withdrawal l-T4 for 4/5 weeks, were studied, aged 18-81 years, 31 females and 4 males; 32 with pap. and 3 folli.c form; 18 for A (G-2A) and 23 for F (G-2B); 6 p carried out 2 studies. One for A and the second as the first control. In G-1, TSH values obtained were 26-360 UI/L ( 83 ± 54. In G-1A : 137 ± 109 and in G-1B 62 ± 52). The 2 tracers 131I and 99mTc-Tc, produce show similar figures. In G-1A all p present thyroid remnants and elevated Tg. In G-1B, 7 p showed positive WBS and Tg; 8 p present Tg positive and WBS negative and 21 WBS and Tg negative. In G-2, the TSH values obtained were 23-179 UI/L (63 ± 39 ); G-2A 71 ± 41 and G-2B 63 ± 42. These findings indicate that the methods is adequate to shortened the time of withdrawal of l-T4 and reduce the signs/symptoms of hypothyroidism to an acceptable status. Also allow us to considered the use of 99mTc as an indicator of existence of remnants, relapses or metastases and avoid blind use of therapeutic activities of 131I.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Thyroid Neoplasms/diagnosis , Thyrotropin-Releasing Hormone/therapeutic use , Carcinoma/diagnosis , Stimulation, Chemical , Thyrotropin-Releasing Hormone/metabolism
2.
Nucl Med Biol ; 27(2): 215-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10773552

ABSTRACT

Exogenous natural surfactant (ENS) labeled with (99m)Tc ((99m)Tc-ENS, 900-1110 MBq), a new radiopharmaceutical for ventilation scintigraphy, was nebulized during 3 min to five volunteers. For comparative purposes, (99m)Tc-diethylenetriamine pentaacetic acid (DTPA) was studied in the same way. (99m)Tc-ENS images were of at least the same quality as (99m)Tc-DTPA images. However, in smoking volunteers, the (99m)Tc-DTPA images show some areas that seemed to be not well-ventilated, although these areas appeared well-ventilated when the study was performed with (99m)Tc-ENS. These results suggest that (99m)Tc-ENS can be used for ventilation scintigraphy to allow the observation of some areas that cannot been visualized using (99m)Tc-DTPA as ventilation agent.


Subject(s)
Lung/diagnostic imaging , Organotechnetium Compounds , Pulmonary Surfactants , Radiopharmaceuticals , Adult , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Radionuclide Imaging , Smoking/metabolism , Technetium Tc 99m Pentetate
4.
Article in English | MEDLINE | ID: mdl-9222389

ABSTRACT

Iron deficiency is one of the most important nutritional problems in the world. The best method to overcome this problem is the fortification of foods with highly bioavailable iron. Fluid milk is a massive consumption food with an easy access and which is generally the only food intake during the first months of life. Therefore the fortification of fluid milk with highly bioavailable iron and no detectable alterations of its sensorial characteristics was studied in the present work. This procedure was made possible using a new type of ferrous sulfate, stabilized and microencapsulated with soy lecitin (SFE-171). The iron concentration of the fortified milk is 12 mg per liter. In order to study the iron absorption from milk fortified with this product, SFE-171 was labeled with 59Fe and given to 29 volunteers with a normal iron status, each of which received an iron quantity of 3 mg in 250 ml of fluid milk. The average iron absorption was (10.2 +/- 4.7) %. This result shows that the iron given in this physicochemical form has the advantage of a high bioavailability and it is possible that this product will be the first attempt for an adequate solution of iron deficiency.


Subject(s)
Ferrous Compounds/pharmacokinetics , Iron, Dietary/blood , Milk, Human/chemistry , Milk/chemistry , Nutritional Physiological Phenomena , Adult , Anemia, Iron-Deficiency/prevention & control , Animals , Biological Availability , Humans , Male
5.
Medicina (B Aires) ; 56(5 Pt 1): 441-7, 1996.
Article in Spanish | MEDLINE | ID: mdl-9239878

ABSTRACT

Hyperparathyroidism is a relatively frequent condition mostly due to a solitary parathyroid adenoma. Although it has been claimed that surgical exploration is the best way to visualize the abnormal parathyroid gland, several imaging techniques have been proposed to localize it in order to simplify and shorten the surgical procedure. Echography, thalium-technetium scintigraphy, computerized tomography and nuclear magnetic resonance have shown a mean sensitivity of 75% which can be increased to about 90% by combining 2 or more of these procedures. In this study, we evaluated the utility of Tc-99m-sestamibi scintigraphy in 13 patients with hyperparathyroidism (11 primary, 2 secondary). High resolution neck echography was carried out in all of the cases. Cervical scans were obtained 10-15 min and 3 hours after giving an i.v. injection of 25 mCi Tc-99m-sestamibi in all the patients; suppression studies with combined 131-I were also done. Positive scans were obtained in 11 out of the 13 patients. Abnormal parathyroid glands were found and surgically excised in all the cases (10 adenomas, 1 carcinoma, 2 hyperplasias). Echographic localization had a sensitivity of only 33.3%. On the contrary, Tc-99m-sestamibi showed a sensitivity of 56% for the whole group, increasing to 82% in the 11 patients with primary hyperparathyroidism whereas the positive predictive value was of 91% and 90%, respectively. We conclude that Tc-99m-sestamibi is a very useful tool in localizing abnormal parathyroid glands and should be the first choice before reoperation after surgical failure or before the first parathyroid surgery whenever it is desired to shorten the surgical and anesthetic duration.


Subject(s)
Hyperparathyroidism/diagnostic imaging , Radiopharmaceuticals , Technetium Tc 99m Sestamibi , Adenoma/diagnostic imaging , Female , Humans , Hyperparathyroidism/surgery , Male , Middle Aged , Parathyroid Glands/diagnostic imaging , Parathyroid Neoplasms/diagnostic imaging , Preoperative Care , Radionuclide Imaging
6.
Eur J Clin Pharmacol ; 48(6): 489-94, 1995.
Article in English | MEDLINE | ID: mdl-8582468

ABSTRACT

The activity of olpadronate labelled with technetium-99m(99mTc) was monitored in plasma and urine samples after single oral (925 MBq 99mTc/10 mg, coadministered with 50 mg cold drug) and intravenous (925 MBq 99mTc/5 mg) administrations to two groups of patients with different rates of bone turnover. The first group comprised high bone turnover (HBTO) patients suffering from Paget's bone disease; the second group comprised patients with normal to low bone turnover (NBTO) having the diagnosis of rheumatoid arthritis and secondary osteoporosis. Kinetic variables were correlated with anthropomorphometric variables, biological markers of bone metabolism and plasma proteins. Data were also obtained after repeatedly dosing the HBTO patients. Additionally, Paget's bone and healthy bone (PB/HB) uptake before and after low-dose oral treatment were assessed by means of scintigraphy. Results showed that most of the kinetic variables did not differ between the two groups of patients, except for a greater Vss and smaller blood area under the curve AUC in the patients with HBTO. After a repeated-dose administration period, the blood AUC activity and Whole Body Retention (WBR) of the HBTO patients tended to be similar to those of the NBTO patients. In both groups, after oral dosing, the Cmax was 20 times lower than the C0.5 after i.v. injection, and the oral bioavailability ranged from 3% to 4%. Finally, the plasma t1/2 beta ranged from 9 to 14 h. Correlation coefficients were obtained from multiple regression analysis; kinetic variables showed very low correlations with anthropomorphometric measurements. In contrast the Vss and WBR were significantly correlated with serum alkaline phosphatase levels and the Vss also with urine hydroxyproline levels. Plasma protein concentration was also correlated with excretion parameters such as CLP and plasma t1/2 beta after an oral dose. Scintigraphic studies in the HBTO group allowed bone selectivity to be seen through skeletal drug uptake. The 15 Pagetic lesions analysed in the HBTO group showed a decrease in PB/HB ratio from 3.8 in the basal study to 2.7 after olpadronate administration for 30 days at the rate of 50 mg/day. In conclusion, the kinetic profile of 99mTc-labelled olpadronate, mainly AUC and WBR, showed a dependence upon bone metabolism and seemed unrelated to body size variables. HBTO patients showed a lower blood AUC but a higher Vss. Both variables may have been reflecting the fact that the drug binds selectively with calcified tissues and, in turn, with the target compartment. Scintigraphy confirmed the labelled-compound bone selectivity as a desirable feature for a bone-scanning agent.


Subject(s)
Bone and Bones/diagnostic imaging , Diphosphonates/pharmacokinetics , Organotechnetium Compounds/pharmacokinetics , Administration, Oral , Arthritis, Rheumatoid/diagnostic imaging , Biological Availability , Blood Proteins/metabolism , Humans , Injections, Intravenous , Osteitis Deformans/diagnostic imaging , Osteoporosis/diagnostic imaging , Radionuclide Imaging
9.
Medicina (B Aires) ; 51(4): 291-5, 1991.
Article in Spanish | MEDLINE | ID: mdl-1821916

ABSTRACT

We have compared two "markers" in the follow up of post treatment (surgery and therapeutical use of I-131) differentiated thyroid carcinoma. In 153 patients, thyroglobulin (Tg) serum levels were measured after withdrawal of I-thyroxine therapy, before performing a whole-body scan (WBS) with iodine-131; in 55 of these patients, Tg was measured again after at least 45 days of I-thyroxine treatment. The patients were followed between 3 and 10 years, and there were 2713 matched studies. Our results indicate for both parameters, false positive and negative values; sensitivity (SE) for WBS was 89% and specificity (SP) 83%; Tg presents a SE of 86% and SP of 83%. Matching both parameters, SE was 95% and SP 98%. The causes of false results are discussed. Tg determinations under I-thyroxine treatment do not permit the establishment of absence of illness; 37.7% of patients with demonstrated metastases or relapse showed negative Tg values that reached pathological values after suspension of I-thyroxine treatment; another 41.4% with elevated Tg values under therapy reached these values after suspension of I-thyroxine. Both markers, when utilized at the same time, offer the best possibilities in the follow-up of differentiated thyroid carcinoma, when determinations are carried out after suspension of hormonal treatment.


Subject(s)
Adenocarcinoma/blood , Adenocarcinoma/diagnostic imaging , Biomarkers, Tumor , Carcinoma, Papillary/blood , Carcinoma, Papillary/diagnostic imaging , Thyroglobulin/blood , Thyroid Neoplasms/blood , Thyroid Neoplasms/diagnostic imaging , Adolescent , Adult , Aged , Biomarkers, Tumor/blood , Female , Follow-Up Studies , Humans , Iodine Radioisotopes , Male , Middle Aged , Neoplasm Metastasis/diagnosis , Neoplasm Recurrence, Local/diagnosis , Radionuclide Imaging , Sensitivity and Specificity , Thyroxine/administration & dosage
11.
Medicina [B Aires] ; 51(4): 291-5, 1991.
Article in Spanish | BINACIS | ID: bin-51292

ABSTRACT

We have compared two [quot ]markers[quot ] in the follow up of post treatment (surgery and therapeutical use of I-131) differentiated thyroid carcinoma. In 153 patients, thyroglobulin (Tg) serum levels were measured after withdrawal of I-thyroxine therapy, before performing a whole-body scan (WBS) with iodine-131; in 55 of these patients, Tg was measured again after at least 45 days of I-thyroxine treatment. The patients were followed between 3 and 10 years, and there were 2713 matched studies. Our results indicate for both parameters, false positive and negative values; sensitivity (SE) for WBS was 89


and specificity (SP) 83


; Tg presents a SE of 86


and SP of 83


. Matching both parameters, SE was 95


and SP 98


. The causes of false results are discussed. Tg determinations under I-thyroxine treatment do not permit the establishment of absence of illness; 37.7


of patients with demonstrated metastases or relapse showed negative Tg values that reached pathological values after suspension of I-thyroxine treatment; another 41.4


with elevated Tg values under therapy reached these values after suspension of I-thyroxine. Both markers, when utilized at the same time, offer the best possibilities in the follow-up of differentiated thyroid carcinoma, when determinations are carried out after suspension of hormonal treatment.

13.
Medicina (B.Aires) ; 51(4): 291-5, 1991. tab
Article in Spanish | LILACS | ID: lil-108060

ABSTRACT

Hemos comparado el valor de los indicadores en el seguimiento del carcinoma tiroideo diferenciado (CaDT): tiroglobulina sérica (Tg) y rastreo corporal total con I-131 (RCT), que fueron realizados entre 3 y 10 años después del tratamiento quirúrgico más dosis terapéutica de I-131. Se realizaron en 153 pacientes 2713 estudios apareados, que se efectuaron con suspensión de la opoterapia por más de 30 días. En 55 pac. se realizaron determinaciones de Tg bajo opoterapia y en 18 en las mismas condiciones, determinaciones seriadas durante 6 meses. Los resultados indican que ambos parámetros pueden presentar falsos positivos y negativos, discutiéndose las razones de los mismos. La sensibilidad (S) para RCT fue de 89% y la especificidad (E) de 83% y para Tg S de 86% y E de 83%; si se consideran ambos parámetros en forma conjunta, S 95% y E 98%. La determinación de Tg bajo opoterapia no permite estabelecer la existencia de metástasis o recidivas con iguales posibilidades que luego de suspensión de la misma. El 37,7% de los casos con enfermedad demostrable, presentaron valores negativos de Tg bajo opoterapia que se elevaron a valores patológicos ...


Subject(s)
Adolescent , Adult , Middle Aged , Humans , Male , Female , Adenocarcinoma/diagnosis , Carcinoma, Papillary/diagnosis , Thyroid Neoplasms/diagnosis , Adenocarcinoma , Carcinoma, Papillary , Follow-Up Studies , Neoplasm Metastasis/diagnosis , Neoplasm Recurrence, Local/diagnosis , Iodine Radioisotopes , Sensitivity and Specificity , Thyroid Neoplasms , Thyroxine/administration & dosage
15.
Medicina [B.Aires] ; 51(4): 291-5, 1991. tab
Article in Spanish | BINACIS | ID: bin-26264

ABSTRACT

Hemos comparado el valor de los indicadores en el seguimiento del carcinoma tiroideo diferenciado (CaDT): tiroglobulina sérica (Tg) y rastreo corporal total con I-131 (RCT), que fueron realizados entre 3 y 10 años después del tratamiento quirúrgico más dosis terapéutica de I-131. Se realizaron en 153 pacientes 2713 estudios apareados, que se efectuaron con suspensión de la opoterapia por más de 30 días. En 55 pac. se realizaron determinaciones de Tg bajo opoterapia y en 18 en las mismas condiciones, determinaciones seriadas durante 6 meses. Los resultados indican que ambos parámetros pueden presentar falsos positivos y negativos, discutiéndose las razones de los mismos. La sensibilidad (S) para RCT fue de 89% y la especificidad (E) de 83% y para Tg S de 86% y E de 83%; si se consideran ambos parámetros en forma conjunta, S 95% y E 98%. La determinación de Tg bajo opoterapia no permite estabelecer la existencia de metástasis o recidivas con iguales posibilidades que luego de suspensión de la misma. El 37,7% de los casos con enfermedad demostrable, presentaron valores negativos de Tg bajo opoterapia que se elevaron a valores patológicos ... (AU)


Subject(s)
Adolescent , Adult , Middle Aged , Aged , Humans , Male , Female , Comparative Study , Thyroid Neoplasms/diagnosis , Carcinoma, Papillary/diagnosis , Adenocarcinoma/diagnosis , Thyroid Neoplasms/diagnostic imaging , Carcinoma, Papillary/diagnostic imaging , Adenocarcinoma/diagnostic imaging , Thyroxine/administration & dosage , Iodine Radioisotopes/diagnosis , Neoplasm Metastasis/diagnosis , Neoplasm Recurrence, Local/diagnosis , Sensitivity and Specificity , Follow-Up Studies
16.
J Nucl Med ; 26(10): 1135-9, 1985 Oct.
Article in English | MEDLINE | ID: mdl-4045556

ABSTRACT

We have investigated the possibilities of technetium-99m-(-3-aminohydroxypropylidene)-1-1-bisphosphon ate ([99mTc]APD) as a bone scanning agent in 14 normal subjects and 28 patients. Similar studies in the same normal subjects and patients were carried out with 99mTc-methylene-bisphosphonate ([99mTc]MDP). The compounds were labeled with 99mTc by means of an electrolytical method; the free pertechnetate content was always under 1%. The [99mTc]APD T1/2 of the third component of the disappearance plasma curve in six normal subjects was 152 +/- 46 min (mean +/- s.d.), while the 24-hr whole-body retention (WBR) was 17.6% +/- 4.6. The [99mTc]MDP value of the 24-hr WBR was 28.6% +/- 3.9 (p less than 0.001). The bone/soft-tissue ratio (B/ST) was investigated in eight control subjects on the eleventh thoracic and the fourth lumbar vertebrae. The B/ST ratios were similar for both APD and MDP studies. In 28 patients with suspected bone metastasis or primary bone disease, bone scintigraphy was carried out; both compounds showed similar findings and the same number of positive results. In five of these patients, the lesion/normal bone ratio was determined with values of 4.6 +/- 2.0 in APD studies and 4.8 +/- 2.3 with MDP. APD was also used in 126 patients; no adverse reactions were observed. The APD dose used i.v. for bone scanning was 200-fold less than those employed by mouth per day, for the treatment of bone disease for long periods. In our experience, APD appears to be an adequate agent for bone scintigraphy.


Subject(s)
Bone Diseases/diagnostic imaging , Diphosphonates , Organotechnetium Compounds , Technetium Tc 99m Medronate , Technetium , Adolescent , Adult , Aged , Diphosphonates/chemical synthesis , Diphosphonates/metabolism , Electrolysis/methods , Female , Humans , Isotope Labeling/methods , Male , Middle Aged , Radionuclide Imaging , Technetium/chemical synthesis , Technetium/metabolism , Technetium Tc 99m Medronate/chemical synthesis , Technetium Tc 99m Medronate/metabolism , Time Factors
19.
Rev. biol. med. nuclear ; 14(3): 53-5, 1982.
Article in Spanish | BINACIS | ID: bin-35497

ABSTRACT

Determinado el valor de la T4L serica en el diagnostico tiroideo, se necesario establecer las modificaciones de los niveles de esta hormonal en distintas condiciones fisiologicas, en especial, las producidas por la edad. Se estudiaron 225 sujetos de ambos sexos, eutiroideos, cuyas edades oscilaban entre 6 y 75 anos, en los que se determino, T4, T3, T4L por RIA. Para todo el grupo el valor de la T4L fue 1,41 ng/ 100 ml +/- 0.08 (e.s.). Se observo un descenso de las cifras de T4L, al aumentar la edad de los pacientes desde niveles de 1.57 ng/100 ml +/- 0.03 para el grupo de 6 a 20 anos de edad hasta 1.14ng/ 100 +/- 0.08 para el grupo de mas de 60 anos. Este descenso fue menos acentuado que el registrado para T3 pero mayor que el observado para T4. Se discuten las implicaciones de esta observaciones y se asocia la discrepancia entre las variaciones de T4 y T4L a las modificaciones de las proteinas transportadoras con el incremento de edad


Subject(s)
Child , Adolescent , Adult , Middle Aged , Aged , Humans , Male , Female , Thyroxine
SELECTION OF CITATIONS
SEARCH DETAIL
...